Certara (NASDAQ:CERT) Stock Gets Price Target Bump from Barclays

Certara (NASDAQ:CERT) had its target price boosted by Barclays from $7.50 to $9.00 in a report issued on Wednesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price objective points to a potential downside of 1.75% from the stock’s previous close.

Several other equities research analysts have also commented on the stock. UBS Group restated a “neutral” rating and issued a $10.00 price target on shares of Certara in a report on Wednesday, September 30th. Weiss Ratings raised shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.60.

Certara Trading Down 1.2%

Shares of CERT opened at $9.16 on Wednesday. Certara has a twelve month low of $4.45 and a twelve month high of $13.30. The company has a market cap of $1.40 billion, a P/E ratio of -20.42 and a beta of 1.42. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The company’s fifty day simple moving average is $8.35 and its 200-day simple moving average is $6.80.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The business had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. During the same period in the prior year, the business posted $0.07 earnings per share. Certara’s revenue was down 10.8% on a year-over-year basis. As a group, analysts expect that Certara will post 0.22 EPS for the current year.

Hedge Funds Weigh In On Certara

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Certara during the 2nd quarter worth about $123,259,000. Dimensional Fund Advisors LP increased its holdings in shares of Certara by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock valued at $48,806,000 after purchasing an additional 175,024 shares during the period. Haveli Investment Management LLC acquired a new position in Certara in the 2nd quarter worth approximately $48,470,000. Jefferies Financial Group Inc. purchased a new position in shares of Certara during the second quarter worth $46,446,000. Finally, Fort Washington Investment Advisors Inc. OH raised its stake in shares of Certara by 17.7% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,675,543 shares of the company’s stock valued at $15,251,000 after buying an additional 402,720 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.